• MaxCyte entered a technology license partnership with Genentech to support development of multiple cell therapy programs.
• License gives Genentech access to MaxCyte’s ExPERT GTx platform across select research, clinical development, manufacturing workflows.
• Deal targets ex vivo cell-engineering applications, aiming to streamline progress from early discovery through cGMP manufacturing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MaxCyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210805PRIMZONEFULLFEED9764808) on July 21, 2026, and is solely responsible for the information contained therein.